New advances in chronic hepatitis B

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Purpose of Review: This article reviews recent developments in the evaluation and treatment of chronic hepatitis B (CHB) based on articles published between December 2010 and January 2012. Recent Findings: The majority of patients infected with CHB have not been diagnosed and most at-risk individuals have not been immunized. Progression to cirrhosis depends on hepatitis B virus (HBV) genotype, hepatitis B e antigen (HBeAg) presence, persistently high levels of HBV DNA, and elevated alanine aminotransferase, although hepatitis B surface antigen (HBsAg) kinetics may help predict natural history and antiviral response. Antiviral resistance limits the success of nucleos(t)ide analogs and agents such as entecavir and tenofovir with high potency and high genetic barrier to resistance are considered first-line therapy. Specialized treatment of CHB in pregnancy, coinfection, decompensated cirrhosis, and posttransplant is safe and effective. Summary: The complications of CHB can now be avoided and reversed with potent antiviral suppression of HBV DNA. For now, treatment is long-term and further studies are needed to discern whether sequential or combination therapy may be superior to current monotherapy for certain patients. Increased awareness should improve screening resulting in more frequent treatment and immunization of at-risk individuals toward eventual CHB eradication.

Original languageEnglish (US)
Pages (from-to)193-197
Number of pages5
JournalCurrent Opinion in Gastroenterology
Issue number3
StatePublished - May 1 2012


  • antiviral therapy
  • chronic hepatitis B
  • chronic liver disease
  • nucleoside analogs

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'New advances in chronic hepatitis B'. Together they form a unique fingerprint.

Cite this